

Minnesota Health Care Quality Report

Part 1: Clinical Quality Measures Reported by Medical Groups

COMMUNITY WEBINAR

THURSDAY, SEPTEMBER 21, 2023

Welcome!



Thanks for joining us today!



All webinar participates are in "listen-only" mode. To ask a question, please type your question into the "Q&A" box at the bottom of your screen at any time during the webinar.



MNCM will send a link to the presentation slides and the recording to webinar attendees later this week.



MNCM Members, Thank you!

Health Plan Members





PrimeWest





🐼 Hennepin Health

MEDICA

Medical Group Members



www.mncm.org/get-involved

MNCM Mission Supporter Program

Financial support is essential to sustain and grow our objective, unbiased work. Your support helps assure our independent work continues. It's an opportunity for your organization to demonstrate its support and commitment to improving health care quality, equity, and affordability while strengthening our work.

Current Silver Level Supporters






www.mncm.org/mission-supporter-program



MNCM empowers health care decision makers with meaningful data to drive improvement.



improvement

MN Community MEASUREMENT

Value-based

payment

Reducing

disparities

Research partnerships

Agenda



Report Overview



Key Findings Care delivered in 2022



Audience Q&A



Health Care Quality Report

Part 1

Measures reported by medical groups

- Colorectal Cancer Screening
- Optimal Asthma Control (Adults & Children)
- Optimal Diabetes Care
- Optimal Vascular Care
- Adolescent Mental Health and/or Depression Screening
- Depression Suite (Adults & Adolescents)
 - o Follow-up PHQ-9/9M at 6/12 Months
 - o Response at 6/12 Months
 - o Remission at 6/12 Months

September 2023

Part 2

Measures reported by health plans

- Avoidance of Antibiotic Treatment in Acute Bronchitis/Bronchiolitis
- Breast Cancer Screening
- Cervical Cancer Screening
- Childhood Immunization Status (Combo 10)
- Chlamydia Screening in Women
- Controlling High Blood Pressure
- Eye Exam for Patients with Diabetes
- Follow-up for Children Prescribed ADHD Medication
- Immunization for Adolescents (Combo 2)
- Osteoporosis Management in Women with Fracture
- Spirometry Testing in the Assessment and Diagnosis of COPD

December 2023

Part 3


High Performers

Spotlight report that highlights the top performing medical groups across all quality measures

January 2024



Current Report



MINNESOTA HEALTH CARE QUALITY REPORT

PART 1: CLINICAL QUALITY MEASURES REPORTED BY MEDICAL GROUPS

Results for care delivered in 2022 | Report released August 2023

MN Community Measuremen

Report can be found at <u>mncm.org</u> > Reports & Data > Community Reports

What's inside?

- Summary of performance rates with achievable benchmark goals by measure
- Trend in performance rates across multiple years for each measure, including comparison to 2019 rates (i.e., pre-pandemic)
- Variation in performance rates across medical groups for each measure
- Variation in performance rates across Minnesota three-digit ZIP code regions




Benchmark Analysis

Adults

	(\bigcirc	\square		$\overline{\mathbf{v}}$		
QUALITY MEASURE		2022 Statewide Average	2022 Benchmark	Gap	Minimum	Maximum	Variation Min/Statewide Average/Benchmark
Preventive Health & Chronic Conditions	Colorectal Cancer Screening	67.8%	71.6%	64,549	0.0%	85.1%	
	Optimal Asthma Control	50.3%	67.2%	24,260	0.0%	100.0%	
	Optimal Diabetes Care	44.6%	48.4%	13,151	7.2%	56.5%	
	Optimal Vascular Care	55.3%	59.2%	7,623	20.0%	68.3%	
Depression Care	PHQ-9/9M Utilization	76.5%	97.6%	41,616	0.0%	100.0%	
	Follow-up PHQ-9/9M at Six Months	47.3%	56.1%	11,992	0.0%	76.2%	
	Response at Six Months	17.9%	21.8%	5,811	0.0%	35.5%	
	Remission at Six Months	10.1%	12.2%	3,470	0.0%	22.2%	
	Follow-up PHQ-9/9M at 12 Months	44.4%	52.2%	11,011	0.0%	69.9%	
	Response at 12 Months	17.4%	19.7%	4,678	0.0%	33.8%	
	Remission at 12 Months	10.1%	12.4%	3,670	0.0%	21.5%	

Benchmark: 90th percentile of medical groups or 90th percentile of patients, whichever is lower. This method prevents the benchmark from being too heavily influenced by only a few medical groups or by medical groups with small numbers of patients.

Gap: The additional number of patients who would reach optimal status or goal if all medical groups' rates were at least at benchmark.






Benchmark Analysis

Gap Example

QUALI	TY MEASURE	2022 Statewide Average	2022 Benchmark	Gap	
8 5	Colorectal Cancer Screening	67.8%	71.6%	64,549	>
Preventive Health Chronic Condition	Optimal Asthma Control	50.3%	67.2%	24,260	
sventive Ironic C	Optimal Diabetes Care	44.6%	48.4%	13,151	
Pre C	Optimal Vascular Care	55.3%	59.2%	7,623	
	PHQ-9/9M Utilization	76.5%	97.6%	41,616	
	Follow-up PHQ-9/9M at Six Months	47.3%	56.1%	11,992	
Care	Response at Six Months	17.9%	21.8%	5,811	
Depression Care	Remission at Six Months	10.1%	12.2%	3,470	
Depr	Follow-up PHQ-9/9M at 12 Months	44.4%	52.2%	11,011	
	Response at 12 Months	17.4%	19.7%	4,678	
	Remission at 12 Months	10.1%	12.4%	3,670	





Rates Over Time

Adults

MEASURE		MEASUREMENT YEAR					
		2018	2019	2020^	2021	2022	
ih & ons	Colorectal Cancer Screening	71.2%	73.2% 🔺	70.6% 🔻	72.2% 🔺 🤇	67.8% ▼*	
Healt	Optimal Asthma Control	53.3%	53.4%	46.6% 🔻	50.3% 🔺	50.3%	
Preventive Health & Chronic Conditions	Optimal Diabetes Care	44.9%	45.4% 🔺	40.6% 🔻	43.6% 🔺 🄇	44.6%	
Preve Chro	Optimal Vascular Care	61.1%	60.3% 🔻	53.8% 🔻	56.5% 🔺 🔇	55.3% 🔻	
	PHQ-9/9M Utilization	N/A	77.7%	68.7% 🔻	71.7% 🔺 🤇	76.5%	
	Follow-up PHQ-9/9M at Six Months	N/A	48.5%	47.9% 🔻	45.3% 🔻 🤇	47.3%	
Care	Response at Six Months	N/A	19.4%	18.9%	18.1% 🔻	17.9%	
Depression	Remission at Six Months	N/A	11.3%	11.0%	10.3% 🔻	10.1%	
Depre	Follow-up PHQ-9/9M at 12 Months	N/A	41.8%	39.6% 🔻	43.9% 🔺	44.4%	
(Response at 12 Months	N/A	17.0%	16.5% 🔻	18.1% 🔺 🤇	17.4%	
(Remission at 12 Months	N/A	10.1%	9.9%	10.6% 🔺 🤇	10.1%	

- Significantly higher than previous year (based on 95% confidence interval)
- ▼ Significantly lower than previous year (based on 95% confidence interval)
- N/A Measure underwent significant changes in 2019 so comparison to prior years is not available
- ^ Due to the COVID-19 pandemic, we urge caution in using 2020 data for comparison to other years and to draw general conclusions about quality of care.
- * The eligible age range for the Colorectal Cancer Screening measure was expanded from 50-75 to 45-75 in 2022MY to reflect updated USPSTF recommendations and to align with NCQA's measure.



Rates Over Time


Optimal Diabetes & Vascular Care

	\SURE	MEASUREMENT YEAR					
ME	ISURE	2018	2019	2020^	2021	2022	
	Optimal Care (Composite)	44.9%	45.4% 🔺	40.6% 🔻	43.6% 🔺	44.6% 🔺	
Care	Blood Pressure Control (<140/90)	83.1%	83.1%	76.0% 🔻	79.0% 🔺	79.7% 🔺	
etes Ci	Daily Aspirin Use (If ischemic vascular disease is present)	99.4%	99.3% 🔻	99.1% 🔻	99.1%	98.7%	
Optimal Diabetes	HbA1c Control (< 8.0)	69.5%	70.2% 🔺	67.2% 🔻	70.5% 🔺	71.8% 🔺	
Optim	Statin Use (Unless contraindicated)	88.1%	88.3%	87.4% 🔻	87.9% 🔺	88.0%	
	Tobacco-free (Not currently using tobacco)	84.0%	84.2%	84.0%	84.1%	84.6% 🔺	
	Optimal Care (Composite)	61.1%	60.3% 🔻	53.8% 🔻	56.5% 🔺	55.3% 🔻	
ır Care	Blood Pressure Control (<140/90)	83.7%	83.9%	76.9% 🔻	79.9% 🔺	80.5% 🔺	
/ascula	Daily Aspirin Use (Unless contraindicated)	92.5%	90.9% 🔻	88.0% 🔻	89.8% 🔺	87.3% 🔻	
Optimal Vascular Care	Statin Use (Unless contraindicated)	91.6%	91.7%	90.9% 🔻	91.5% 🔺	91.4%	
	Tobacco-free (Not currently using tobacco)	82.4%	82.5%	82.0% 🔻	82.4% 🔺	82.4%	

- Significantly higher than previous year (based on 95% confidence interval)
- ▼ Significantly lower than previous year (based on 95% confidence interval)
- N/A Measure underwent significant changes in 2019 so comparison to prior years is not available
- [^] Due to the COVID-19 pandemic, we urge caution in using 2020 data for comparison to other years and to draw general conclusions about quality of care.



Comparison to Pre-Pandemic Rates Adults



▼ Significantly lower than 2019 rate




Colorectal Cancer Screening

Update to Age Range

45-75

Percentage of adults ages 50-75 who are up-to-date with the appropriate screening for colorectal cancer. Appropriate screenings include one of the following:


- **Colonoscopy** during measurement period or nine years prior
- Flexible sigmoidoscopy during the measurement period or four years prior
- **CT colonography** during the measurement year or four years prior
- **FIT-DNA** during measurement year or two years prior
- **gFOBT or FIT** during measurement year



Measurement Year




Rate Variation by Medical Group





Rate Variation by Geography

Colorectal Cancer Screening



3-digit ZIP Code	Major City	Rate
Minnesot	68.0%	
550xx	Stillwater	68.2%
551xx	St. Paul	67.1% 🔻
553xx	Minnetonka	68.7% 🔺
554xx	Minneapolis	65.0% 🔻
556xx	Two Harbors	65.4% 🔻
557xx	Cloquet	68.0%
558xx	Duluth	70.8% 🔺
559xx	Rochester	70.6% 🔺
560xx	Mankato	67.5% 🔻
561xx	Windom	63.8% 🔻
562xx	Willmar	70.2% 🔺
563xx	St. Cloud	72.4% 🔺
564xx	Brainerd	70.1% 🔺
565xx	Detroit Lakes	71.5% 🔺
566xx	Bemidji	64.4% 🔻
567xx	Thief River Falls	66.1% 🔻

Minnesota resident average includes only patients submitted with a Minnesota ZIP code as their place of residence.

- Significantly higher than Minnesota resident average (based on 95% confidence interval)
- Significantly lower than Minnesota resident average (based on 95% confidence interval)



Key Findings Comparison of 2022 rates to 2021 rates



Significant Increases

- Adolescent Mental Health and/or Depression Screening
- Optimal Diabetes Care
- Adult Dep: Follow-up at 6 Months
- Adol Dep: Follow-up at 6 Months
- Adult Dep: PHQ-9/9M Utilization
- +6.0 Adol Dep: PHQ-9/ 9M Utilization



Significant Decreases

- Adult Dep: Remission at 12 Months
- Adult Dep: Response at 12 Months
- Optimal Vascular Care
- Optimal Asthma Control Children

-4.4 • Colorectal Cancer Screening

Age expansion contributed to significant decrease, but other factors contributed as well



Key Findings Comparison of 2022 rates to 2019 rates (pre-pandemic)



+3.3

Significantly Higher

- Adult Dep: Response at 12 Months
- Adol Dep: Follow-up PHQ-9/9M at Six Months
- Adult Dep: Follow-up PHQ-9/9M at 12 Months
- Adol Dep: PHQ-9/9M Utilization
- Adolescent Mental Health
- and/or Depression Screening



Significant Decreases

- Optimal Diabetes Care
- Adol Dep: Remission at 12 Months
- Adol Dep: Remission at Six Months
- Adult Dep: Follow-up PHQ-9/9M at Six Months
- Adult Dep: Remission at Six Months
- Adult Dep: PHQ-9/9M Utilization
- Adol Dep: Response at Six Months
- Adult Dep: Response at Six Months
- Optimal Asthma Control Adults
- Optimal Asthma Control Children
- Optimal Vascular Care
- -5.4 Colorectal Cancer Screening



Key Findings Variation among Medical Groups

Adults	Children/Adolescents
 Largest variation: Optimal Asthma Control PHQ-9/9M Utilization 	 Largest variation: AMH Screening PHQ-9/9M Utilization
 21.5% 0% Smallest variation: Depression – Remission at 12 Months 	Smallest variation: Depression – Remission at 12 Months



Key Findings Variation among Three-Digit ZIP Code Regions



- Colorectal Cancer Screening
- Optimal Asthma Control Adults
- Optimal Diabetes Care
- Optimal Vascular Care
- AMH Screening
- Optimal Asthma Control Children



- Colorectal Cancer Screening
- Optimal Asthma Control Adults
- Optimal Diabetes Care
- Optimal Vascular Care
- AMH Screening
- Optimal Asthma Control Children
- Adol Dep: Remission at Six Months

• Thief River Falls area (567xx)

- Colorectal Cancer Screening
- Optimal Asthma Control Adults
- Optimal Diabetes Care
- Optimal Vascular Care
- Adult Dep: Remission at Six Months
- AMH Screening
- Optimal Asthma Control Children



Audience Q & A



Please type your questions into the "Q&A" box at the bottom of your screen



Thank you for joining us!



MNCM will send a link to presentation slides and the recording to webinar attendees later this week.



Please reach out to us at <u>support@mncm.org</u> with additional questions related to available data or how our data can support your work.



Join our mailing list for newsletters and other updates: https://mncm.org/news/#newsletters

